ATE194291T1 - Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus - Google Patents

Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus

Info

Publication number
ATE194291T1
ATE194291T1 AT96933810T AT96933810T ATE194291T1 AT E194291 T1 ATE194291 T1 AT E194291T1 AT 96933810 T AT96933810 T AT 96933810T AT 96933810 T AT96933810 T AT 96933810T AT E194291 T1 ATE194291 T1 AT E194291T1
Authority
AT
Austria
Prior art keywords
antibodies
virus
synzytial
monoclonal antibodies
antibodies against
Prior art date
Application number
AT96933810T
Other languages
English (en)
Inventor
Glenn R Pilkington
Page S Gilmour
Robert M Chanock
James E Crowe Jr
Brian R Murphy
Original Assignee
Intracel Corp
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intracel Corp, Us Health filed Critical Intracel Corp
Application granted granted Critical
Publication of ATE194291T1 publication Critical patent/ATE194291T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96933810T 1995-09-18 1996-09-18 Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus ATE194291T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US393195P 1995-09-18 1995-09-18
PCT/US1996/014937 WO1997010846A1 (en) 1995-09-18 1996-09-18 Neutralizing monoclonal antibodies to respiratory syncytial virus

Publications (1)

Publication Number Publication Date
ATE194291T1 true ATE194291T1 (de) 2000-07-15

Family

ID=21708285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933810T ATE194291T1 (de) 1995-09-18 1996-09-18 Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus

Country Status (11)

Country Link
US (3) US7488477B2 (de)
EP (2) EP0853487B1 (de)
AT (1) ATE194291T1 (de)
AU (2) AU7240096A (de)
CA (2) CA2230127A1 (de)
DE (1) DE69609188T2 (de)
DK (1) DK0853487T3 (de)
ES (1) ES2148799T3 (de)
GR (1) GR3034349T3 (de)
PT (1) PT853487E (de)
WO (2) WO1997010846A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU4002001A (en) * 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP2284192A3 (de) 2002-11-08 2011-07-20 Ablynx N.V. Antikörper aus Camelidae zur sublingualen Verabreichung
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
ES2579805T3 (es) * 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
MX2009009226A (es) 2007-03-06 2009-10-28 Symphogen As Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
EP1997830A1 (de) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
EP2201040A1 (de) * 2007-09-24 2010-06-30 Vanderbilt University Monoklonale antikörper gegen das respiratorische synzytialvirus und ihre verwendung
AU2008312457B2 (en) * 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
KR100938998B1 (ko) * 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
US8591961B2 (en) 2008-09-04 2013-11-26 Allergan, Inc. Aesthetic treatment of scars and aging skin
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
EP2591000B1 (de) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EA039222B1 (ru) * 2016-07-27 2021-12-20 Мерк Шарп И Доум Корп. Антитело, нейтрализующее респираторно-синцитиальный вирус человека
EP3525820A4 (de) * 2016-10-17 2020-09-16 Vanderbilt University Humane respiratorische synzytial-virus-antikörper und verfahren zur verwendung davon
KR102695416B1 (ko) 2016-10-21 2024-08-13 아디맵 엘엘씨 항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법
CA3040893A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3529272A2 (de) 2016-10-21 2019-08-28 Adimab, LLC Antikörper gegen das respiratorische synzytial-virus und verfahren zu deren erzeugung und verwendung
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11202007241WA (en) * 2018-01-31 2020-08-28 Wistar Inst Nucleic acid antibody constructs for use against respiratory syncytial virus
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
DK0671927T3 (da) * 1992-09-16 2003-04-22 Us Gov Health & Human Serv Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
AU3660893A (en) * 1993-01-29 1994-08-15 Med Immune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1995003832A1 (en) * 1993-07-30 1995-02-09 Thomas Jefferson University Intracellular immunization
WO1995004081A1 (en) * 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS

Also Published As

Publication number Publication date
EP0851924A1 (de) 1998-07-08
US20040005324A1 (en) 2004-01-08
US7488477B2 (en) 2009-02-10
CA2230116A1 (en) 1997-03-27
CA2230127A1 (en) 1997-03-27
US20120087909A1 (en) 2012-04-12
AU7240096A (en) 1997-04-09
AU7075496A (en) 1997-04-09
DE69609188T2 (de) 2000-12-21
WO1997010846A1 (en) 1997-03-27
US20090110684A1 (en) 2009-04-30
WO1997011177A1 (en) 1997-03-27
PT853487E (pt) 2000-11-30
GR3034349T3 (en) 2000-12-29
EP0853487A1 (de) 1998-07-22
US8221759B2 (en) 2012-07-17
DK0853487T3 (da) 2000-10-23
ES2148799T3 (es) 2000-10-16
DE69609188D1 (de) 2000-08-10
EP0853487B1 (de) 2000-07-05

Similar Documents

Publication Publication Date Title
DE69609188D1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
EP0671927A4 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialviru.
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
YU36096A (sh) Neutrališuća visoko afinitivna humana monoklonalna antitela specifična u rsv f-protein i postupci za njihovu proizvodnju
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
BR0113112A (pt) Anticorpos, de integrina antidual, composições, métodos e usos
WO2003092630A3 (en) Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
WO2003048337A3 (en) Antibody to latent membrane proteins and uses thereof
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
EP1433792A8 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
PT914417E (pt) Dnase ii humana
WO2002085924A3 (en) ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE